PDHX and hepatocellular carcinoma: Notably, PDHX Lys 488 acetylation levels were positively correlated with the clinical stage of HCC (Fig. 1D–G), suggesting that PDHX Lys 488 acetylation can be exploited as a biomarker and potentially, a therapeutic target for HCC diagnosis and treatment.